The American Society of Clinical Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASCO has been an ...
Conquer Cancer®, the ASCO Foundation and Pfizer Inc. are collaborating to offer a Quality Improvement grant funding opportunity for healthcare systems, hospitals, cancer centers and other patient care ...
All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent criteria across all applications for each ...
The American Society of Clinical Oncology (ASCO) is a medical professional oncology society committed to conquering cancer through research, education, prevention, and delivery of high-quality patient ...
These awards are generously supported by Hologic, Inc. and Generous supporters of Conquer Cancer®, the ASCO Foundation.
The worldwide need to provide palliative cancer care to relieve the suffering of patients and families living with cancer is greater than ever. Over the past decade ASCO, its members, and other ...
Conquering cancer through research, education, and promotion of the highest quality patient care. ASCO is supported by its affiliate organization, Conquer Cancer, the ASCO Foundation, which funds ...
In addition to gaining a global network of more than 50,000 peers, ASCO membership includes a range of benefits to enhance your career, practice, and research.
*Information may not display until shortly after posted time, pending site load times. Deadline to Apply for ASCO Media Credentials and/or Register for Access to Meeting Content (In Person or Online ...
When submitting an abstract or late-breaking placeholder to any ASCO Meeting, the First Author must agree to the following Prior Presentation/Publication Policy and ...
Conquer Cancer®, the ASCO Foundation, has a mission to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer. Through our Grants & Awards Program, we are ...